Canaccord Genuity Maintains a 'Buy' on Vascular Solutions (VASC); Q4 Mixed; 2012 Looks Like Transition Year

Canaccord Genuity maintains a 'Buy' on Vascular Solutions (NASDAQ: VASC) price target cut to $14.00.

Analyst, Jason R. Mills, said, "Q4 sales were slightly lower than expected, as the launch of Pronto V4 was delayed again. VASC expects its new ClosureFAST reprocessing deal to contribute $1-5M in 2012, albeit it maintained $94-96M revenue guidance. Q1 guidance was set below consensus, implying a more back-end-loaded 2012, helped by several new product launches in H1/12E."

For an analyst ratings summary and ratings history on Vascular Solutions click here. For more ratings news on Vascular Solutions click here.

Shares of Vascular Solutions closed at $10.80 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• DA Davidson Starts Comfort Systems USA (FIX) at Buy
• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics